AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 FEB 21 - (NewsRx.com & NewsRx.net) --
by Michelle Marble, staff medical writer -- What makes an effective vaccine against Mycobacterium tuberculosis? Researchers in the United States want to know.
"Previous studies in murine and human models have suggested an important role for human leukocyte antigen (HLA) Ia-restricted CD8(+) T cells in host defense to Mycobacterium tuberculosis (Mtb)," wrote D.M. Lewinsohn and colleagues, Oregon Health Sciences University. "Therefore, understanding the antigens (Ags) presented via HLA-Ia will be important in understanding the host response to Mtb and in rational vaccine design." Lewinsohn et al. published their study in the Journal of Immunology.
"We have used monocyte-derived dendritic cells in a limiting dilution analysis to generate Mtb-specific CD8(+) T cells," explained the authors. "Two HLA-Ia-restricted CD8(+) T-cell clones derived by this method were selected for detailed analysis."
One of the clones was HLA-B44 restricted, and the other was HLA-B14 restricted. Lewinsohn et al. observed that both reacted with Mtb-infected targets, but neither reacted with bacillus Calmette-Guerin (BCG)-infected targets.
The Ag identified for both clones was culture filtrate protein 10 (CFP10)/Mtb11. This is a 10.8-kDa protein that is not expressed by bacillus Calmette-Guerin. The researchers observed that anti-class I antibody (Ab) and anti-HLA-B,C Abs inhibited both clones ("Classically restricted human CD8(+) T lymphocytes derived from Mycobacterium ...
Source: HighBeam Research, Antigenic Specificity of Infected Cells Defined.(Brief Article)